MK International Medical - Japanese high-class cell therapy services
MK International Medical - Japanese high-class cell therapy services
Stem cell and immune cell therapy expert
Director of N2 Clinic Yotsuya
Dr. Hiroshi Terunuma
Dr. Hiroshi Teranuma, Director, has been a pioneer in the field of cell culture in Japan since 2004, and has focused on research and development of immune cell therapy, stem cell therapy, and stem cell supernatant StemSup®.
With many years of experience in treating patients using cellular regenerative medicine, some of Dr. Terunuma's research results and treatment effects have been published in more than 100 scientific papers, making significant contributions to the field of regenerative medicine.
Experience:
1985 Graduated from Tohoku University, Faculty of Medicine
1989 Completed Doctoral Program, Graduate School of Medicine, Tohoku University
1989 Assistant Professor, Northeastern University School of Medicine
1990 Visiting Fellow, Wistar Institute, USA
1992 Research Assistant Professor, University of Miami School of Medicine, USA
1993 Assistant Professor, Northeastern University School of Medicine
1995 Specialist, Japan International Cooperation Organization
1997 Lecturer, Yamanashi Medical University
2004 Established Biotherapy Institute of Japan, Inc.(BIJ)
2007 Director, Department of Immunotherapy and Hyperthermia, Tokyo Clinic
2007 Director, Department of Immunotherapy and Hyperthermia, Southern Tohoku Medical Clinic
2021 Director of N2 Clinic Yotsuya
In order to provide highly safe and high quality regenerative medicine to all clients, specialized cell culture techniques, equipment, facilities and extensive experience are essential.
Our partner organization, Biotherapy Institute of Japan, Inc.(BIJ), was established in 2004 and has more than 20 years of experience in cell cultivation. It has been certified as a cell culture processing facility by the Pharmaceutical and Medical Device Agency (PMDA), an independent administrative body commissioned by the Ministry of Health, Labour and Welfare. Moreover, it has many patents and achievements in the field of cell culture and is a world leader in culture technology.
In order for all clients to receive the highest quality regenerative medicine, all cells and preparations cultured and prepared at the Institute are subject to thorough quality control and safety testing.
Approved Facility Number:
株式会社日本バイオセラピー研究所 豊洲本社CPF: FA3150009
株式会社日本バイオセラピー研究所 筑波研究所CPF: FA3200003
